Immunotherapy-associated complete heart block in a patient with NSCLC: A case report and literature review

Respiratory Medicine Case Reports

Aditi Kalotra¹  Sean Kandel²  Jasmine Varughese³  Wylie Hosmer³  Alexander Vartanov³  Shovendra Gautam³ 

[1] Corresponding author.;Department of Medicine, Hospital of Central Connecticut, 100 Grand Street, New Britain, CT, 06052, USA;Department of Medicine, University of Connecticut School of Medicine, 263 Farmington Avenue L2104, Farmington, CT, 06030, USA;

关键词: Immunotherapy;    Cardiotoxicity;    Lung cancer;    Conduction disorder;    Myocarditis;   

DOI  :  

来源: DOAJ

【 摘 要 】

The role for PD-1/PD-L1 and CTLA-4 targeted immunotherapy is well outlined in the treatment of metastatic NSCLC. Increased survival benefit supports the use of these medications and the development of next-generation agents with improved efficacy and favorable side-effect profiles. The prevalence of immunotherapy-associated cardiotoxicity (IAC) has grown significantly over the past two years as awareness of this toxicity class has emerged. High-grade conduction disorders comprise a subset of cardiotoxicities with a high case fatality rate. We presented a case of suspected combination ipilimumab-nivolumab associated 3rd degree heart block. The onset of this event was 16 days after immunotherapy initiation. A literature review has suggested that over 75% of cases of cardiotoxicity are observed within the first 6 weeks. We present findings from an interrogation of the FDA Adverse Event Reporting System (FAERS) and provide clinical guidance for the early identification of high-risk patients.

【 授权许可】

Unknown